Apolipoprotein E Gene Variation in Pakistani Subjects with Type 2 Diabetes with and without Cardiovascular Complications

被引:1
|
作者
Nadeem, Shehwar [1 ]
Maqbool, Tahir [1 ]
Qureshi, Javed Anver [1 ]
Altaf, Awais [1 ]
Naz, Sadia [2 ]
Azhar, Muzammal Mateen [2 ]
Ullah, Inam [1 ]
Shah, Tawaf Ali [3 ]
Qamar, Muhammad Usman [4 ,5 ]
Salamatullah, Ahmad Mohammad [6 ]
机构
[1] Univ Lahore, Ctr Res Mol Med, Inst Mol Biol & Biotechnol, Lahore 54660, Pakistan
[2] Univ Lahore, Dept Allied Hlth Sci, Lahore 54660, Pakistan
[3] Shandong Univ Technol, Coll Agr Engn & Food Sci, Zibo 255049, Peoples R China
[4] Univ Geneva, Dept Med, Div Infect Dis, CH-1211 Geneva, Switzerland
[5] Govt Coll Univ Faisalabad, Fac Life Sci, Inst Microbiol, Faisalabad 38000, Pakistan
[6] King Saud Univ, Coll Food & Agr Sci, Dept Food Sci & Nutr, Riyadh 11451, Saudi Arabia
来源
MEDICINA-LITHUANIA | 2024年 / 60卷 / 06期
关键词
apolipoprotein E; polymorphisms; ischemic heart disease; stroke; MELLITUS; DYSLIPIDEMIA; EPIDEMIOLOGY; RISK; ASSOCIATION; PREVALENCE; DISEASE;
D O I
10.3390/medicina60060961
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Apolipoprotein E (APOE) gene polymorphism has been implicated in the pathogenesis of various metabolic disorders, including type 2 diabetes mellitus (T2DM). Type 2 diabetes mellitus (T2DM) is a major public health concern worldwide, including in Pakistan. Cardiovascular problems linked with T2DM have a significant impact on individuals and society. The goal of this study is to investigate the relationship between Apolipoprotein E (ApoE) genotypes, dyslipidemia, and cardiovascular complications such as ischemic heart disease (IHD) and stroke. Methods: This study was carried out on 260 subjects divided into controls and diabetics. The diabetics were further divided into four subgroups such as D1: diabetics without cardiovascular issues, D2: diabetics with heart disease, D3: diabetics with stroke, and D4: diabetics with both heart disease and stroke. Anthropometric parameters (age, BMI) and risk factors (smoking, diabetes duration, hypertension) were assessed in all groups. Serum levels of TC, TG, LDL, HDL, VLDL, creatinine, BSF, and HbA1c were also measured. Apolipoprotein E gene polymorphism was determined using PCR-RFLP. Results: Hypertension, BMI, and dyslipidemia are defined as elevated levels of total cholesterol, triglycerides, LDL, and VLDL, and decreased levels of HDL. Uncontrolled hyperglycemia (elevated fasting blood sugar and glycated hemoglobin) in T2DM was linked to vascular complications such as IHD and stroke. Hypertension was prevalent in 79.3% of the population. Stage 2 hypertension was more prevalent in all age groups. It was also noted that common genotypes in the Pakistani population are 3/3, 4/4, 2/3, and 3/4. The frequency of genotypes 3/4 and 2/3 is highest in diabetics with stroke. Genotype 3/3 is present frequently in diabetics with IHD/stroke and patients with both these complications. However, genotype 4/4 is most frequently found in diabetics with IHD. Conclusions: It is concluded that BMI, hypertension, hyperglycemia, atherosclerosis, and dyslipidemia are linked with cardiovascular complications of type 2 diabetes. Apolipoprotein E gene polymorphism is associated with cardiovascular disease in patients with diabetes by affecting the lipid profile.
引用
收藏
页数:23
相关论文
共 50 条
  • [21] Apolipoprotein B and E levels after weight loss with and without remission of type 2 diabetes
    Melhem, S.
    Zhyzhneuskaya, S.
    Peters, C.
    Barnes, A.
    Hollingsworth, K. G.
    Sattar, N. S.
    Lean, M. E. J.
    Taylor, R.
    Al-Mrabeh, A.
    DIABETIC MEDICINE, 2020, 37 : 40 - 40
  • [22] Association of hypertriglyceridaemia with complications in subjects with type 2 diabetes
    Penno, G.
    Solini, A.
    Zoppini, G.
    Fondelli, C.
    Orsi, E.
    Zerbini, G.
    Trevisan, R.
    Vedovato, M.
    Gruden, G.
    Lamacchia, O.
    Baroni, M. G.
    Pugliese, G.
    DIABETOLOGIA, 2013, 56 : S100 - S100
  • [23] VARIATION IN THE APOLIPOPROTEIN-B GENE AND DEVELOPMENT OF TYPE-2 DIABETES-MELLITUS
    HOULSTON, RS
    SNOWDEN, C
    LAKER, MF
    ALBERTI, KGMM
    HUMPHRIES, SE
    DISEASE MARKERS, 1991, 9 (02) : 87 - 96
  • [24] The relationship of the apolipoprotein E gene polymorphism in Turkish Type 2 diabetic patients with and without nephropathy
    M. Erdogan
    Z. Eroglu
    C. Biray
    M. Karadeniz
    S. Cetinkalp
    B. Kosova
    C. Gunduz
    N. Topcuoglu
    G. Ozgen
    C. Yilmaz
    Journal of Endocrinological Investigation, 2009, 32 : 219 - 222
  • [25] Autoantibodies against an immunodominant epitope from apolipoprotein B and risk of cardiovascular events in subjects with type 2 diabetes
    Sant'Anna, Viviane Aparecida R.
    Izar, Maria Cristina O.
    Gidlund, Magnus
    Fonseca, Henrique Andrade R.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 116 : 152 - 154
  • [26] Serum Uromodulin Predicts Cardiovascular Events both in Patients With and in Subjects Without Type 2 Diabetes
    Leiherer, Andreas
    Muendlein, Axel
    Saely, Christoph H.
    Rein, Philipp
    Vonbank, Alexander
    Kinz, Elena
    Brandtner, Eva M.
    Fraunberger, Peter
    Drexel, Heinz
    DIABETES, 2016, 65 : A81 - A81
  • [27] Apolipoprotein C3 Gene Variants and Risk of Developing Type 2 Diabetes in Saudi Subjects
    Alharbi, Khalid K.
    Hussain, Tajamul
    Alharbi, Fawiziah K.
    Tabassum, Shaik Nazia
    Mohammed, Arif A.
    Gambhir, Dikshit
    Ali Khan, Imran
    METABOLIC SYNDROME AND RELATED DISORDERS, 2015, 13 (07) : 298 - 303
  • [28] The relationship of the apolipoprotein E gene polymorphism in Turkish Type 2 diabetic patients with and without nephropathy
    Erdogan, M.
    Eroglu, Z.
    Biray, C.
    Karadeniz, M.
    Cetinkalp, S.
    Kosova, B.
    Gunduz, C.
    Topcuoglu, N.
    Ozgen, G.
    Yilmaz, C.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (03) : 219 - 222
  • [29] Editorial: Preventing cardiovascular complications of type 2 diabetes
    Baldassarre, Maria Pompea Antonia
    Paolucci, Teresa
    Park, Kyoungmin
    Pipino, Caterina
    FRONTIERS IN ENDOCRINOLOGY, 2024, 15
  • [30] Sulfonylureas and cardiovascular complications of type 2 diabetes mellitus
    Nedosugova, L., V
    DIABETES MELLITUS, 2013, 16 (02): : 26 - 35